Your browser doesn't support javascript.
loading
Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy.
Tzannou, Ifigeneia; Nicholas, Sarah K; Lulla, Premal; Aguayo-Hiraldo, Paibel I; Misra, Anisha; Martinez, Caridad A; Machado, Annette A; Orange, Jordan S; Piedra, Pedro A; Vera, Juan F; Leen, Ann M.
  • Tzannou I; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
  • Nicholas SK; Solid Organ Transplant Immunology, Section of Immunology, Allergy and Rheumatology.
  • Lulla P; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
  • Aguayo-Hiraldo PI; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
  • Misra A; Department of Molecular Virology and Microbiology, Baylor College of Medicine.
  • Martinez CA; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
  • Machado AA; Department of Molecular Virology and Microbiology, Baylor College of Medicine.
  • Orange JS; Center for Human Immunobiology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.
  • Piedra PA; Department of Molecular Virology and Microbiology, Baylor College of Medicine.
  • Vera JF; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
  • Leen AM; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.
J Infect Dis ; 216(6): 678-687, 2017 09 15.
Article en En | MEDLINE | ID: mdl-28934427
ABSTRACT
Human metapneumovirus (hMPV) is a respiratory virus detected in ≥9% of allogeneic hematopoietic stem cell transplant (HSCT) recipients, in whom it can cause significant morbidity and mortality. Given the lack of effective antivirals, we investigated the potential for immunotherapeutic intervention, using adoptively transferred T cells. Thus, we characterized the cellular immune response to the virus and identified F, N, M2-1, M, and P as immunodominant target antigens. Reactive T cells were polyclonal (ie, they expressed CD4 and CD8), T-helper type 1 polarized, and polyfunctional (ie, they produced interferon γ, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and granzyme B), and they were able to kill autologous antigen-loaded targets. The detection of hMPV-specific T cells in HSCT recipients who endogenously controlled active infections support the clinical importance of T-cell immunity in mediating protective antiviral effects. Our results demonstrate the feasibility of developing an immunotherapy for immunocompromised patients with uncontrolled infections.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Infecciones por Paramyxoviridae / Metapneumovirus Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Infecciones por Paramyxoviridae / Metapneumovirus Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article